Orexo Overview
- Year Founded
-
1995
- Status
-
Public
- Employees
-
55
- Stock Symbol
-
ORX
- Investments
-
3
- Share Price
-
$0.09
- (As of Friday Closing)
Orexo General Information
Description
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
Contact Information
Website
www.orexo.comCorporate Office
- Virdings Allé 32A
- 754 50 Uppsala
- Sweden
Corporate Office
- Virdings Allé 32A
- 754 50 Uppsala
- Sweden
Orexo Stock Performance
As of 13-Nov-2026, Orexo’s stock price is $0.09. Its current market cap is $4.9M with 56.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.09 | $0.09 | $0.08 - $2.44 | $4.9M | 56.1M | 387K | $0.77 |
Orexo Financials Summary
As of 30-Sep-2026, Orexo has a trailing 12-month revenue of $1.34M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 21,643 | 155,054 | 98,384 | 82,707 |
| Revenue | 1,341 | 2,646 | 2,808 | 60,099 |
| EBITDA | (34,300) | (33,212) | (32,300) | (2,926) |
| Net Income | 41,942 | 65,071 | (19,195) | (12,071) |
| Total Assets | 37,714 | 141,579 | 53,909 | 78,708 |
| Total Debt | 660 | 53,413 | 43,141 | 47,409 |
Orexo Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Orexo Comparisons
Industry
Financing
Details
Orexo Competitors (32)
One of Orexo’s 32 competitors is Moberg Pharma, a Formerly VC-backed company based in Bromma, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Moberg Pharma | Formerly VC-backed | Bromma, Sweden | ||||
| Assertio Holdings | Formerly VC-backed | Lake Forest, IL | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Mundipharma International | Private Equity-Backed | Cambridge, United Kingdom | ||||
| Alkermes | Formerly VC-backed | Dublin, Ireland |
Orexo Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Orexo Patents
Orexo Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202319899-D0 | New composition | Pending | 22-Dec-2023 | ||
| GB-202315885-D0 | New composition | Pending | 17-Oct-2023 | ||
| GB-202308121-D0 | New composition | Pending | 31-May-2023 | ||
| GB-202308123-D0 | New copmosition | Pending | 31-May-2023 | ||
| AU-2024280073-A1 | Spray-dried compositions comprising adrenergic receptor modulators | Pending | 31-May-2023 | A61K9/0043 |
Orexo Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Orexo Acquisitions (3)
Orexo’s most recent deal was a Merger/Acquisition with PharmaKodex for . The deal was made on 21-Aug-2009.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PharmaKodex | 21-Aug-2009 | Merger/Acquisition | Drug Discovery | ||
| Biolipox | 23-Nov-2007 | Merger/Acquisition | Drug Discovery | ||
| CePep | 29-Aug-2003 | Merger/Acquisition | Biotechnology |
Orexo ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
38.92 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,999
Rank
Percentile
Pharmaceuticals
Industry
of 952
Rank
Percentile
Pharmaceuticals
Subindustry
of 438
Rank
Percentile
Orexo Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Biolipox | Solna, Sweden | 2000 |
Orexo FAQs
-
When was Orexo founded?
Orexo was founded in 1995.
-
Where is Orexo headquartered?
Orexo is headquartered in Uppsala, Sweden.
-
What is the size of Orexo?
Orexo has 55 total employees.
-
What industry is Orexo in?
Orexo’s primary industry is Pharmaceuticals.
-
Is Orexo a private or public company?
Orexo is a Public company.
-
What is Orexo’s stock symbol?
The ticker symbol for Orexo is ORX.
-
What is the current stock price of Orexo?
As of 13-Nov-2026 the stock price of Orexo is $0.09.
-
What is the current market cap of Orexo?
The current market capitalization of Orexo is $4.9M.
-
What is Orexo’s current revenue?
The trailing twelve month revenue for Orexo is $1.34M.
-
Who are Orexo’s competitors?
Moberg Pharma, Assertio Holdings, Evonile Pharma, Mundipharma International, and Alkermes are some of the 32 competitors of Orexo.
-
What is Orexo’s annual earnings per share (EPS)?
Orexo’s EPS for 12 months was $0.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
